Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review reports that topical minoxidil remains the primary treatment for androgenetic alopecia, while oral and sublingual forms offer alternative options, each with varying efficacy and side effects.

This study developed and validated a precise and rapid HPLC method to simultaneously determine Minoxidil and Finasteride in pharmaceuticals, demonstrating successful application for routine quality control without interference from excipients.

This study found that a topical gel containing Minoxidil and Tofacitinib citrate showed promise for treating alopecia areata, with formulation F5 demonstrating effective drug release and stability in evaluations.

In this study, the novel isoprenylcysteine analog SIG-1451 was shown to inhibit pro-inflammatory cytokine release in various cell-based assays relevant to allergic dermatitis, acting on targets such as IL-4 and IL-6 with potential anti-inflammatory benefits.

This study found that apple polyphenol extract, particularly oligomeric procyanidins, inhibited pancreatic lipase activity and reduced triglyceride absorption in both mice and humans.

This review discusses nanoparticle-based topical delivery systems for treating skin diseases and presents no new clinical findings; it emphasizes natural polymer-based nanoparticles and future applications like targeted drug delivery.

This review discusses strategies for developing semi-solid topical generic products to match the quality of reference-listed drugs, using concepts like quality by design and reverse-engineering, but reports no new results.

This study found that IMT-P8, a novel cell-penetrating peptide, effectively facilitated the dermal delivery of proteins and peptides in mouse skin and cell lines, suggesting potential for topical applications in cosmetics and skin diseases.

This study suggests that finasteride-loaded liquid crystalline nanoparticles could be a viable alternative to oral administration for treating androgenetic alopecia due to their controlled release and skin permeation properties.

In this study, 3% topical minoxidil showed some efficacy in hair regrowth for patients with extensive alopecia areata, especially those with less than total scalp hair loss, but did not lead to complete remission.

This study found that 5% topical minoxidil solution led to greater hair regrowth in severe alopecia areata patients compared to 1% minoxidil, although most regrowth was not cosmetically acceptable.

This study found that twice-daily application of 3% topical minoxidil maintained a higher nonvellus hair count compared to once-daily application over 2 years and 9 months in men with male pattern baldness.

This study found that both topical and oral finasteride significantly reduced plasma DHT after one week, with lower finasteride plasma exposure for the topical formulation.

This review examines topical immunotherapy for severe alopecia areata, noting that diphencyprone and squaric acid dibutylester are non-mutagenic options with similar efficacy but different practical considerations, and reports no new clinical results.

This study found that topical minoxidil increased heart rate and had significant effects on cardiac volumes and mass compared to placebo, but its long-term safety remains uncertain.

This study observed that 2% minoxidil solution was at least as effective as 3% for increasing hair growth and stabilizing bald areas in men with male pattern baldness.

This study found that topical melatonin solution was associated with positive effects on hair density and reduction in hair loss for androgenetic alopecia, with good tolerability reported in several clinical trials.

This case report describes a patient with an allergic sensitization to minoxidil, indicating that such patients should pursue alternative therapies to treat androgenetic alopecia.

This study suggests that hairless dogs' skin shows sensitivity to topical corticosteroids, highlighting their potential as a model for studying the efficacy and adverse effects of these treatments on skin.

This study found that adapalene-loaded solid lipid microparticles may enhance targeted drug delivery into sebum due to their similarity to sebum components, although both this formulation and a standard cream showed equivalent follicular penetration.

In this study, the combination of finasteride and minoxidil significantly increased hair growth in balding male stumptail macaques compared to each drug alone.

Minoxidil effectively treats hair loss, with better results in women.

This study demonstrated that topical oleuropein induced hair growth in mice by activating the Wnt10b/β-catenin signaling pathway and increasing expression of several growth-related genes in skin tissue.

This study found that a combination of topical minoxidil and finasteride helped maintain hair density in patients with androgenetic alopecia after initial oral finasteride treatment.

This study found that topical application of 2% minoxidil solution was not effective in improving erectile dysfunction in the majority of participants.

This study observed that two out of twelve patients showed hair growth without the usual shedding after hair transplant surgery when treated with topical minoxidil, suggesting its potential as an adjunctive therapy during recovery.

In this study, 53% of patients with male pattern baldness experienced significant hair growth with one year of topical minoxidil, while 95% rated its effectiveness as moderate or excellent.

This study found that both ciclosporin A and topical therapy were effective in reducing alopecia and scaling in dogs with idiopathic sebaceous adenitis, with evidence suggesting improved outcomes when both treatments are combined.

This case report discusses a 32-year-old man's treatment for advanced androgenetic alopecia using a combination of topical minoxidil and oral finasteride, but no clinical outcomes are detailed.

This review discusses the potential of nanotechnology-based formulations for delivering topical minoxidil to improve hair loss treatment outcomes and reports no new clinical results, urging further research into their benefits and safety considerations.